Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.
As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.
Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down.
InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend.
Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.
What's Happening With VSTM Stock Today?
Verastem Inc (VSTM) stock is lower by -6.2% while the S&P 500 has gained 0.03% as of 11:10 AM on Thursday, Oct 12. VSTM is down -$0.51 from the previous closing price of $8.22 on volume of 17,799 shares. Over the past year the S&P 500 has gained 22.00% while VSTM has gained 41.99%. VSTM lost -$4.40 per share in the over the last 12 months.
To see InvestorsObserver's Sentiment Score for Verastem Inc click here.
More About Verastem Inc
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic, and other advanced cancers.
Click Here to get the full Stock Report for Verastem Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
